Olema Oncology Announces Preclinical Data for KAT6A Degraders
Olema Oncology reported preclinical data on its selective KAT6A degraders in ER+/HER2- breast cancer models, which will be presented at the 38th EORTC-NCI-AACR Symposium.
Stocks · News reference
Olema Oncology announced its participation in three upcoming healthcare investor conferences scheduled for late November and early December 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Olema Oncology reported preclinical data on its selective KAT6A degraders in ER+/HER2- breast cancer models, which will be presented at the 38th EORTC-NCI-AACR Symposium.
Olema Pharmaceuticals, Inc. has officially changed its corporate name to Olema Oncology, Inc., effective November 12, 2026.
Filed: 2026-11-12 AccNo: 0001193125-26-458572 Size: 751 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Olema Pharmaceuticals, Inc. has officially changed its corporate name to Olema Oncology, Inc., effective November 12, 2026. The company's stock will continue trading on Nasdaq under ticker symbol OLMA. The clinical-stage biopharmaceutical company is advancing its lead product candidate palazestrant (OP-1250) through two Phase 3 trials, with top-line data from the OPERA-01 trial expected in Q1 2027.
Olema Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2026, and announced the appointment of Jason O'Byrne as Chief Financial Officer.